.1 ml semaglutide Ozempic 1 mg Injection for Type 2 Diabetes Control — Mountainside Medical and a shorter life GLP-1 | Semaglutide for Weight

extended-release formulations may be affected by semaglutide's gastric emptying effects Mental health monitoring is essential

doi: 10.1002/14651858.CD008274.pub3

For those looking for a long-term solution or support in managing diabetes, Semaglutide is a safe and effective choice

Zealand Pharma has completed Phase 1 testing but has not announced a Phase 3 start date, citing the need for "formulation improvements to increase bioavailability and reduce skin irritation." A realistic timeline: Phase 3 could start late 2026, with 52-week data by mid-2028 and an FDA submission in late 2028 at the earliest

and is a co-author on a paper reporting a secondary analysis of data from the ACTION-IO study (funded by Novo Nordisk) (no payments received)

Nature 461, 762767